Gilead Sciences Inc. ($GILD) Stock Forecast: Up 5.1% Today

What is Gilead Sciences Inc.?

Gilead Sciences (GILD) is a biopharmaceutical company known for its HIV prevention therapies and innovative drug launches. The overall market sentiment for GILD has been positive due to strong earnings performance.

Why is Gilead Sciences Inc. going up?

GILD stock is up 5.1% on Feb 11, 2026 19:26

• Gilead Sciences reported upbeat Q4 earnings, beating estimates and driven by growth in HIV prevention therapies and the launch of Yeztugo, leading to a bullish market movement.
• Despite weaker-than-expected fiscal 2026 guidance, analysts raised price targets and reiterated positive ratings, indicating confidence in the company's future prospects.
• Institutional investors adjusting their stakes and new acquisitions in GILD suggest continued interest and support in the company's growth trajectory.
• The market reaction to Gilead's earnings beat and dividend increase showcases investor optimism, despite concerns about future guidance and performance in non-HIV segments.

GILD Price Chart

GILD Technical Analysis

GILD News

Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Gilead Sciences reported upbeat fourth-quarter earnings, beating consensus estimates for both EPS and revenue, driven by strong growth in its HIV prevention therapies and the launch of Yeztugo. Despite the strong quarterly results, the company issued weaker-than-expected fiscal 2026 guidance, causing its shares to fall in pre-market trading. Following the earnings announcement, several analysts, including Needham, Scotiabank, and Cantor Fitzgerald, reiterated their positive ratings and raised their price targets for Gilead.

https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50539905/gilead-analysts-boost-their-forecasts-after-upbeat-q4-earnings

Rhumbline Advisers Sells 15,602 Shares of Gilead Sciences, Inc. $GILD

Rhumbline Advisers reduced its stake in Gilead Sciences (NASDAQ:GILD) by 0.7% in the third quarter, selling 15,602 shares. Despite this, other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Invesco Ltd. increased their positions in the biopharmaceutical company. Gilead Sciences recently announced a dividend increase and reported earnings that beat analyst estimates, although its FY 2026 guidance was below consensus, leading to some negative market reaction.

https://www.marketbeat.com/instant-alerts/filing-rhumbline-advisers-sells-15602-shares-of-gilead-sciences-inc-gild-2026-02-11/

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52

Amgen Inc. (NASDAQ:AMGN) is set to increase its dividend to $2.52, resulting in a dividend yield similar to the industry average at 2.8%. The company's earnings are projected to cover future distributions, with the payout ratio estimated at 61%, indicating sustainability. While Amgen has a strong history of growing dividends, its earnings growth has been slow, which could limit future dividend increases.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-nasdaqamgn-is-increasing-its-dividend-to-252-1

Caprock Group LLC Invests $7.23 Million in Gilead Sciences, Inc. $GILD

Caprock Group LLC has acquired a new stake worth approximately $7.23 million in Gilead Sciences, Inc. The article also notes that other institutional investors have adjusted their holdings in Gilead, and provides analyst ratings, financial performance, and recent insider trading activities for the company. Gilead Sciences recently announced an increase in its quarterly dividend and reported Q4 earnings that surpassed analyst estimates, despite current-year guidance being below expectations.

https://www.marketbeat.com/instant-alerts/filing-caprock-group-llc-invests-723-million-in-gilead-sciences-inc-gild-2026-02-11/

Gilead Sciences exceeds Q4 2025 earnings and revenue forecasts

Gilead Sciences reported strong Q4 2025 results, with product sales of $7.9 billion and adjusted EPS of $1.86, both surpassing analyst expectations, primarily driven by its HIV portfolio. Despite the earnings beat, the stock experienced a post-market decline due to high expectations for the new HIV prevention drug Yeztugo and softness in non-HIV segments like cell therapy. Gilead issued 2026 guidance projecting product sales of $29.6-$30 billion and non-GAAP EPS of $8.45-$8.85, along with a raised quarterly dividend, signaling confidence in future cash flow.

https://mlq.ai/news/gilead-sciences-exceeds-q4-2025-earnings-and-revenue-forecasts/

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 10.3% Today

DaVita Inc. ($DVA) Stock Forecast: Up 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 5.2% Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.6% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 8.9% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.7% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

Gilead Sciences Inc. Price History

22.00.2026 - GILD Stock was up 5.6%

• Gilead Sciences experienced a strong bullish movement today, with a 4.0% increase in stock price, reaching $129.11.
• The bullish trend can be attributed to positive news surrounding the cell therapy market dynamics, where Gilead Sciences is a key player, showcasing advancements in research, clinical applications, and strategic partnerships.
• Additionally, the positive forecast issued by Rothschild & Co Redburn, raising the price target for Gilead Sciences to $159, further fueled investor confidence in the company's growth prospects.
• The recent study by Arcellx indicating the efficacy of CAR T-cell therapy in treating multiple myeloma and the strong earnings performance of Gilead Sciences in the past quarter have also contributed to the bullish sentiment surrounding the stock.

05.00.2026 - GILD Stock was down 1.9%

• Gilead Sciences Inc. (GILD) faced a bearish market movement possibly due to the news of Repare Therapeutics announcing Gilead's acquisition of RP-3467 for up to $30 million. This acquisition might have raised concerns among investors about the potential impact on Gilead's financials or strategic direction.
• The appointment of Sung Lee, a finance leader with experience in biopharmaceutical companies including Gilead Sciences, to Tango Therapeutics' Board of Directors might have diverted some attention and resources away from Gilead, leading to a negative sentiment in the market.
• The strategic shift towards oncology and diversified product offerings by another company could have also influenced investors to reevaluate Gilead's position in the competitive landscape, contributing to the bearish movement.
• The evaluation of Gilead Sciences Inc. as a potential investment, contrasting its stability with operational risks like patent cliffs and trial failures, might have prompted some investors to reposition their portfolios, impacting GILD's stock performance negatively.

11.01.2026 - GILD Stock was up 5.1%

• Gilead Sciences reported upbeat Q4 earnings, beating estimates and driven by growth in HIV prevention therapies and the launch of Yeztugo, leading to a bullish market movement.
• Despite weaker-than-expected fiscal 2026 guidance, analysts raised price targets and reiterated positive ratings, indicating confidence in the company's future prospects.
• Institutional investors adjusting their stakes and new acquisitions in GILD suggest continued interest and support in the company's growth trajectory.
• The market reaction to Gilead's earnings beat and dividend increase showcases investor optimism, despite concerns about future guidance and performance in non-HIV segments.